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ABSTRACT 
Celiac disease (CD) is an autoimmune enteropathy induced by the ingestion of gluten in genetically predisposed 
individuals who carry the HLA-DQ2 or -DQ8 alleles. The immune response is abnormal in celiac disease with small 
intestinal epithelial damage via CD8+CD4- intraepithelial lymphocytes. The etiology is multifactorial involving genetic 
and environmental factors, an abnormal immune response, and intestinal dysbiosis. The innate and acquired T-cell 
mediated immunity play important roles in the pathogenesis of this disease, particularly CD4+ Th17 cells, which have 
been shown to have critical functions in host defense against bacterial pathogens and in the inflammatory responses to 
deamidated gluten peptides. We review what is known about the interaction between immune system and intestinal 
microbiota in the pathogenesis of celiac disease.  
Keywords: Celiac disease, Immune response, HLA, Interleukin, Microbiota. 
(Please cite as: Cicerone
 
C, Nenna
 
R, Pontone
 
S. Th17, intestinal microbiota and the abnormal immune response 
in the pathogenesis of celiac disease. Gastroenterol Hepatol Bed Bench 2015;8(2):117-122). 
 
Introduction  
  
1 Celiac disease (CD) is a chronic autoimmune 
disorder induced by the ingestion of gluten 
proteins of wheat (gliadins) and other related 
cereals (rye and barley) proteins (hordeins and 
secalins) in genetically predisposed individuals 
(1). This autoimmune disorder affects the small 
bowel and often produces symptoms as diarrhea, 
malabsorption, and extraintestinal symptoms (1). 
The HLA locus is the main genetic influence. For 
example the HLA-DQA1*05:01 and DQB1*02:01 
alleles forming the particular DQ2.5 haplotype 
confer high susceptibility to CD (2). A recent 
study also reveals that the HLA-DQ2 genotype 
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strongly influences the intestinal colonization of 
infants at family risk of developing CD. Infants 
with high genetic risk of developing the disease 
(HLA-DQ2 carriers) show reduced abundance of 
Actinobacteria (Bifidobacterium species) and 
increased abundance of Firmicutes (3). The typical 
histological features of CD include atrophy of the 
small intestinal villi, hyperplasia of the crypts, and 
a marked infiltration of the lamina propria and 
intraepithelial compartments with inflammatory 
cells (4).  
The prevalence of CD in adults in the United 
States ranges from 0.7% to 2.3%, and 1.3% in 
Italian school-age children (5). In addition, several 
studies have shown that, despite a prevalence 
comparable to those of European nations, CD 
remains underdiagnosed in the United States (6,7). 
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The only treatment for CD is lifelong adherence to 
a gluten-free diet. It has been demonstrated to 
improve the symptoms, reduce the risk of 
malignancy, and impart other health benefits such 
as an improvement in bone mineral density (8,9).  
Recently, oats have been receiving increasing 
interest as food to celiac patients. The 
incorporation of oats into a gluten-free diet 
provides high fiber and vitamin B. However, it is 
recommended that individuals with CD should 
have both initial and long-term assessments by a 
health professional when introducing pure oats 
into a gluten-free diet (10). Real A et al., indicates 
that some cultivars of oats can be a safe part of a 
gluten free diet suggesting that there is wide range 
of variation of potential immunotoxicity of oat 
cultivars (11). 
 
Immunopathology of celiac disease 
and role of IL-17 
 
It is well known that innate and acquired T-cell 
mediated immunity play important roles in the 
pathogenesis of the disease. In CD, the T-cell 
mediated adaptive response is mediated by CD4+ 
Th1 lymphocytes in the lamina propria. 
Deamidated gluten peptides are presented to 
CD4+ Th cells with subsequent release of 
inflammatory cytokines. We know that the lamina 
propria of the small intestine contains large 
numbers of two homeostatically regulated and 
developmentally related populations of CD4 T 
cells, IL-17+ helper Th17 cells and Foxp3+ 
regulatory T cells (Treg) (14-15). Th17 cells 
produce the cytokines IL-17 (also known as IL-
17A), IL-17F, and IL-22. Among these, IL-17 has 
been the most thoroughly studied and is 
considered the signature effector cytokine for this 
subset. In humans and mice, the IL-17 cytokine 
family consists of six members: IL-17A (also 
referred to as IL-17), IL-17B, IL-17C, IL-17D, IL-
17E (also known as IL-25) and IL-17F (16-18).  
Similar to Th1 or Th2 cells, in vivo, differentiation 
of naıve CD4+ T cells into Th17 cells requires T 
cell receptor recognition of its cognate antigen 
presented on major histocompatibility complex 
(MHC) class II by professional antigen-presenting 
cells (APCs), such as dendritic cells (Dcs).  
 Th17 cell differentiation in vitro from naïve T 
cells requires furthermore, the coordinated action 
of multiple cytokines including TGF-β (17-20) 
and also has been proved in vivo, that certain 
bacterial species are potent immune stimulators 
(21,22). 
Functionally, IL-17A participates in inflammatory 
responses inducing neutrophil granulopoiesis by 
stimulating epithelial cells to secrete granulocyte 
colony-stimulating factor (G-CSF). Furthermore, 
IL-17A and IL-17F can directly recruit and 
activate neutrophil cellular responses at sites of 
inflammation (14). Given the expanding roles of 
IL-17A and IL-22 in mediating innate barrier 
responses, it is not surprising that the IL-17A IL-
22 axis is emerging as a central element of 
mucosal immunity to microbial challenge. In fact, 
Th17 cells have been shown to have critical 
functions in host defense against bacterial and 
fungal pathogens, particularly those encountered 
at mucosal surfaces (23-25). Recent studies 
confirmed that mucosal IL-17A response was 
elevated at the late stage of CD when villous 
atrophy has developed. Mucosal IL-17A displayed 
elevated expression in children with untreated CD 
when compared to GFD-treated children and 
children with potential CD (26-29). 
Another study revealed elevated interleukin IL-17 
responses after exposure to wheat gliadin in acute 
CD, but not in potential CD, thus indicating the 
association of upregulated IL-17 pathway with 
villous atrophy. However, T-cell clones reactive 
with deamidated gliadin peptide did not show IL-
17 secretion, which suggests that activation of IL-
17 may not be induced directly by dietary gluten 
but rather develops at later stage of mucosal 
inflammation (30,31). 
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IL-17 in mucosal antimicrobial defense has been 
shown to contribute to the gut barrier function and 
upregulation of IL-17 decrease the dissemination 
of pathogens from the intestinal lumen (32). On 
the other hand, commensal bacteria can induce 
mucosal IL-17 response (33-34) and it is possible 
that changes in microbiota could be responsible 
for the upregulation of IL-17 when villous atrophy 
develops. 
The cytokine profile can be different in patients 
with refractory CD (RCD) or active CD. In the 
RCD the symptoms/signs of malabsorption and 
villous atrophy persist or recur despite a strict 
GFD for more than 12 months and in the absence 
of other disorders (35). 
A recent study (36) have analyzed on duodenal 
biopsies, inflammatory cytokines by real-time 
PCR and ELISA in patients with RDC, and active 
CD. IFN (interferon)-γ and IL (interleukin)-21 
transcripts were increased in active CD patients 
but not in RCD patients as compared to normal 
controls, whereas IL-17A RNA was upregulated 
in both active CD and RCD. The findings indicate 
that the profile of mucosal effector cytokines 
differs between RCD and active CD and suggest 
that TNF-α, IL-6 and IL-17A, but not Th1-type 
cytokines, could drive the detrimental response in 
this condition. 
 
Intestinal microbiota, immune 
system and celiac disease 
The composition of intestinal microbiota and 
intestinal dysbiosis has been implicated in the 
pathogenesis of celiac disease (36,37). The 
intestinal microbiota is the collection of microbes 
that reside in the gastrointestinal (GI) tract and is 
comprised of over 1000 different species that 
contributes 3.3 million unique microbial genes in 
the GI tract of humans (38,39). This intricate 
microbial system includes bacteria, which live in a 
symbiotic relationship with their host, and some 
microbes, which have potentially pathogenic 
characteristics. There are four dominant phyla: 
Firmicutes, Bacteroidetes, Actinobacteria and 
Proteobacteria (38). Firmicutes and Bacteroidetes 
account for >90% of the bacterial population in the 
colon while Actinobacteria and Proteobacteria 
(which includes Enterobacteriaceae) are regularly 
present but are scarce (<1%–5%) (36). 
Molecular techniques have shown that, compared to 
the fecal and duodenal microbiota of healthy 
individuals, the fecal and duodenal microbiota of 
CD patients is characterized by the presence of 
higher numbers of gram-negative bacteria 
(bacteroides and enterobacteria) and lower numbers 
of gram-positive bacteria, like bifidobacteria. The 
differences between active and non-active CD seem 
to be associated with a decreased abundance of 
members of the family Streptococcaceae, 
specifically the S. anginosus and S. mutans groups. 
The active phase of the disease was also associated 
with increased proportions of Enterobacteriaceae 
and Staphylococcaceae and, in particular, the 
species Klebsiella oxytoca, S. epidermidis, and S. 
pasteuri. (37,40). 
These alterations are attenuated after long-term 
adherence to a gluten-free diet, but the microbiota is 
not completely restored; in particular, a reduced 
abundance of specific species of Streptococcus (S. 
anginosus and S. mutans) also characterizes the 
microbiota of CD patients with active and non-active 
disease. A recent study (41) showed that the treated 
celiac disease patients with persistent symptoms 
were colonized by different duodenal microbiota in 
comparison with patients without symptoms. The 
treated patients with persistent symptoms had a 
higher relative abundance of Proteobacteria (p=0.04) 
and a lower abundance of Bacteroidetes (p=0.01) 
and Firmicutes (p=0.05). The intestinal microbiota 
plays a crucial role in the development of local and 
systemic immunity, as well as in maintaining colonic 
homeostasis (42,43). For example, to drive the 
expansion of B and T cells in Peyer’s patches and 
mesenteric lymph nodes, especially CD4+ T cells 
(Fig.1) (44). 
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Besides segmented filamentous bacteria, which 
adhere closely to the intestinal epithelium, have 
been shown to induce Th17 responses (32) and 
increase the number of Treg cells in both the small 
intestine and colon (45). 
Although IL-17A and IL-22 secretion can be a 
hallmark of the adaptive phase response to infection, 
it is becoming increasingly clear that bacterial 
pathogens trigger rapid IL-17A- and IL-22-
dependent innate defense in the gut mucosa (46). 
Moreover, the production of these cytokines in the 
intestine seems to be regulated at the homeostatic 
level by the interaction between the host and the 
intestinal microbiota. In a recent study, Jose´ 
Moise´s Laparra and colleagues have demonstrated 
that the administration of Bifidobacterium longum 
CECT 7347, previously selected for reducing gliadin 
immunotoxic effects in vitro, could exert protective 
effects in an animal model of gliadin-induced 
enteropathy by increasing NFkB expression and IL-
10, but reducing TNF-a production. In sensitized 
gliadin-fed animals, CD4+, CD4+/Foxp3+ and 
CD8+ T cells increased, whereas the administration 
of B. longum CECT 7347 reduced CD4+ and 
CD4+/Foxp3+ cell populations and increased CD8+ 
T cell populations (47). These results confirmed and 
another study (48) that showed that Bifidobacterium 
strains with immunoregulatory properties have been 
shown to suppress the pro-inflammatory cytokine 
pattern induced by the altered colonic microbiota of 
CD patients. 
 
Conclusions 
In conclusions this review suggests that the IL-17A 
producing cells play a major role in the pathogenesis 
of CD, and that both gluten and bacteria provoke an 
IL-17A response in the intestinal mucosa of CD 
patients. The upregulation of IL-17 immunity is 
associated with untreated CD and especially villous 
atrophy, whereas mucosal IL-17 immunity is not 
 
Figure 1. Expansion of B and T cells in Peyer’s patches in response to gliadin. 
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present in potential or GFD treated CD. IL-17 is a 
marker of active CD and its role as a predictive 
biomarker of villous atrophy should be evaluated. 
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